What is Olysio®?
UPDATE: Janssen Therapeutics discontinued Olysio effective May 25, 2018.
On November 5, 2013 the U.S. Food and Drug Administration approved Olysio (simeprevir), a hepatitis C virus NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C genotype 1 infection as a component of a combination antiviral treatment regimen.
The active ingredient of Olysio is 150 mg of simeprevir, taken once per day with food.
Last Updated: May 2018
A New Chronic Hepatitis C Treatment - Olysio (simeprevir). http://www.olysio.com/, Janssen Therapeutics. Retrieved May 8, 2015.
FDA Approved New Treatment for Hepatitis C Cure. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376449.htm, U.S. Food and Drug Administration. Retrieved May 8, 2015.
Helpful Tips When Facing Chronic Hepatitis C. http://www.olysio.com/sites/default/files/pdf/fact-sheets.pdf, Janssen Therapeutics. Retrieved May 8, 2015.
Highlights of Prescribing Information - OLYSIO. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf, Janssen Therapeutics. Retrieved May 8, 2015.